|
May 10
|
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight
|
|
May 9
|
Royalty Pharma Reports First Quarter 2024 Results
|
|
May 9
|
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
|
|
May 4
|
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be $0.21
|
|
Apr 20
|
Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21
|
|
Apr 19
|
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
|
|
Apr 17
|
Royalty Pharma Declares Second Quarter 2024 Dividend
|
|
Mar 30
|
Royalty Pharma plc's (NASDAQ:RPRX) Stock Has Shown A Decent Performance: Have Financials A Role To Play?
|
|
Feb 28
|
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
|
|
Jan 8
|
Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
|
|
Nov 27
|
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
|
|
Nov 26
|
Royalty Pharma plc (NASDAQ:RPRX) is a favorite amongst institutional investors who own 69%
|
|
Nov 13
|
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
|
|
Nov 13
|
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
|
|
Nov 8
|
Royalty Pharma Reports Third Quarter 2023 Results
|
|
Sep 12
|
Are Royalty Pharma plc's (NASDAQ:RPRX) Mixed Financials Driving The Negative Sentiment?
|
|
Aug 24
|
Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)
|
|
Jul 18
|
Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023
|
|
Jul 17
|
Royalty Pharma Declares Third Quarter 2023 Dividend
|